PHARMA THIRD PARTY CONTRACT MANUFACTURER OF METFORMIN & GLIMEPIRIDE
The combination is designed in order to lower the blood glucose level by orally taken products. Metformin is an oral antihyperglycemic product which is used for type-II diabetic patients which are non-insulin dependent class of products called Biguanides. Glimepiride is a long-acting product classified as sulfonylureas used only for lowering blood glucose level.
Class Biguanides & sulfonylureas
Mechanism of action
In type-II diabetes, insulin secretion from the pancreas is too little & liver releases glucose in excess, Metformin acts on the liver to slow the release of glucose & also slows the absorption of glucose from the intestine. Glimepiride stimulates the release of insulin by binding to ATP-sensitive potassium channel receptor which reduces the conductance of potassium as a result depolarization of membrane occurs which stimulates calcium ion concentration to induce insulin secretion.
Bioavailability of Metformin 50-60%
Absorption of Glimepiride-completely absorbed (100%)
Protein binding of Glimepiride-99.5%
Half-life in plasma of Metformin-6.2 hours
Half-life in plasma of Glimepiride-5 hours
Metformin & Glimepiride combination may be prescribed for the management of Diabetes (Type-2), Reduces blood glucose level thereby prevents Kidney damage, and Blindness, Nerve problems & Sexual function problems & Loss of limbs. Metformin may prevent the cardiovascular disease.
Allergic skin reaction
Vomiting, metallic taste & diarrhea
Aspirin (increase mean AUC of glimepiride)
Furosemide (increase Cmax of metformin)
Each tablet contains 250 mg Metformin & 1MG glimepiride & 500 mg Metformin & 2 mg glimepiride.
Consult with Doctor or Pharmacist.
We are the supplier of Metformin & Glimepiride also a trader of Metformin & Glimepiride.
* The following symptoms are suggestive & needs to be confirmed before promoting or coating anywhere & anybody whom so ever. Power2pharma.com & its parent company NEWS pharma Pvt. Ltd. is not responsible for its authenticity.